Ongoing ACR advocacy efforts are working to keep biologic drugs accessible to rheumatology patients, defending the ability of rheumatology practices to use the complex chemotherapy codes for administration of biologic therapies.
The ACR’s RISE Registry & Rheumatology Research Foundation Launch Award to Support Early Career Professionals
A new award from the ACR’s RISE Registry and the Rheumatology Research Foundation supports early career rheumatology researchers and clinicians who leverage the registry’s real-world data in research projects.
Letter to the Editor: Weathering Storms
We read the article, “Rheumatologists Share Lessons Learned in the Wake of Hurricane Ida” (July 2022, The Rheumatologist), with great interest. This poignant account of the impacted patients and rheumatologists provides invaluable planning tips regarding medication loss, access to pharmacies and medical records, and strategies to avoid practice losses. The critical lessons presented in this…
COVID-19 Vaccinations in Immune-Compromised Patients
A prospective observational study by Syversen et al. found that patients with immune-mediated inflammatory diseases (IMID) had an attenuated serologic response to the standard two-dose vaccine regimen but a third dose was safe and effective.
2023 Proposed Rule for the Quality Payment Program Released
The ACR RISE Registry staff highlights need-to-know information and key changes for the 2023 performance year as outlined in the proposed rule released July 7.
Clinical Challenges in SLE: Glucocorticoids—How Much Is Too Much?
Glucocorticoids remain a prominent part of care for many patients with SLE but can have toxic side effects; this EULAR 2022 session discussed one institution’s approach to lower the dosage.
Refractory Gout Is a Myth: Tips from an Expert
At this EULAR 2022 session, one expert explains why he believes refractory gout is caused by mismanagement and discussed ways around treatment obstacles.
JAK Inhibitors: Are All Promises Fulfilled?
A decade after JAK inhibitors were approved, this EULAR 2022 session looks at whether the drugs have lived up to expectations.
How to Connect with Your Members of Congress During the August Recess
Many members of Congress return to their home states and districts in August, making it a great time to engage them in local conversations about healthcare policies and how they affect rheumatology practices and patients.
Imaging Modalities in Gout: How to Use them in Clinical Practice
This EULAR 2022 session discussed the increasing role of imaging in the diagnosis of gout.
- « Previous Page
- 1
- …
- 93
- 94
- 95
- 96
- 97
- …
- 814
- Next Page »